Literature DB >> 29486314

Growth Potential of Subdural Hematomas Under Clinical Observation: Which Subdural Hematomas Tend to Grow and Why They Do.

Ziya Asan1.   

Abstract

OBJECTIVE: To study the prognoses of patients with subdural hematoma (SDH) who were not operated on at the time of the first diagnosis and the causes of enlarged hematomas in some patients during the follow-up period.
MATERIALS AND METHODS: The records, service files, and radiologic examination results of the patients with diagnoses of SDH were reviewed. The SDH patients were recorded under 5 different categories: acute SDH (ASDH), subacute SDH (SSDH), chronic SDH (CSDH), acute component with chronic SDH (A-CSDH), and subacute component with chronic SDH (S-CSDH). The symptoms, clinical findings, and progression in the patients were correlated with radiologic examinations.
RESULTS: A total of 291 patients received diagnoses of SDHs: 80 patients with acute, 29 patients with subacute, and 163 patients with chronic hematoma. Thirty-five patients had diagnoses of SDH with a combination of different components. It was determined that in the follow-up period, patients with A-CSDH showed the greatest increase in hematoma size over time and required surgical intervention the most often.
CONCLUSION: SDHs reveal different prognoses in different age groups. Multicomponent SDHs are within the group that shows the greatest increase in size in the follow-up period. SDHs and CSDHs cause recurrent hemorrhages by sustaining the tension on the bridging veins. The greater the hematoma volume, the greater the growth potential of the hematoma tends to be. CSDHs that do not manifest changes in volume for a long time can be monitored without surgical intervention as long as the clinical picture remains stable.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic subdural hematoma; Multicomponent subdural hematoma; Subdural hematoma; Subdural hematoma follow-up; Subdural hematoma risk factors

Mesh:

Substances:

Year:  2018        PMID: 29486314     DOI: 10.1016/j.wneu.2018.02.106

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  1 in total

1.  Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage.

Authors:  Ava E Cascone; Mitchell J Daley; Neil Pan; Eimeira Padilla-Tolentino; Truman J Milling
Journal:  Pharmacotherapy       Date:  2021-05-17       Impact factor: 6.251

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.